



Identification of cystic fibrosis transmembrane conductance regulator as a prognostic marker for juvenile myelomonocytic leukemia via the whole-genome bisulfite sequencing of monozygotic twins and data mining

Tian-Tian Yi¹, Jie-Ming Yu¹, Yi-Yang Liang¹, Si-Qi Wang², Guan-Chuan Lin², Xue-Dong Wu¹

¹Department of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, China; ²Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China

Contributions: (I) Conception and design: GC Lin, TT Yi; (II) Administrative support: XD Wu; (III) Provision of study materials or patients: JM Yu; (IV) Collection and assembly of data: TT Yi, YY Liang, JM Yu; (V) Data analysis and interpretation: GC Lin, SQ Wang; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Xue-Dong Wu. Department of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, China. Email: xuedongwu@163.com; Guan-Chuan Lin. Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China. Email: lyncelot.lin@qq.com.

Background: Linked deoxyribonucleic acid (DNA) hypermethylation investigations of promoter methylation levels of candidate genes may help to increase the progressiveness and mortality rates of juvenile myelomonocytic leukemia (JMML), which is a unique myelodysplastic/myeloproliferative neoplasm caused by excessive monocyte and granulocyte proliferation in infancy/early childhood. However, the roles of hypermethylation in this malignant disease are uncertain.

Methods: Bone marrow samples from a JMML patient and peripheral blood samples from a healthy monozygotic twin and an unrelated healthy donor were collected with the informed consent of the participant's parents. Whole-genome bisulfite sequencing (WGBS) was then performed. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed to analyze specific differentially methylated region (DMG) related genes. The target genes were screened with Cytoscape and Search Tool for the Retrieval of Interacting Genes/Proteins (STRING), which are gene/protein interaction databases. A data mining platform was used to examine the expression level data of the healthy control and JMML patient tissues in Gene Expression Omnibus data sets, and a survival analysis was performed for all the JMML patients.

Results: The STRING analysis revealed that the red node [i.e., the cystic fibrosis transmembrane conductance regulator (*CFTR*)] was the gene of interest. The gene-expression microarray data set analysis suggested that the *CFTR* expression levels did not differ significantly between the JMML patients and healthy controls ($P=0.81$). A statistically significant difference was observed in the *CFTR* promoter methylation level but not in the *CFTR* gene body methylation level. The overall survival analysis demonstrated that a high level of *CFTR* expression was associated with a worse survival rate in patients with JMML ($P=0.039$).

Conclusions: *CFTR* promoter hypermethylation may be a novel biomarker for the diagnosis, monitoring of disease progression, and prognosis of JMML.

Keywords: Bioinformatics analysis; cystic fibrosis transmembrane conductance regulator (*CFTR*); monozygotic twins

Submitted Jul 05, 2022. Accepted for publication Sep 08, 2022.

doi: 10.21037/tp-22-381

View this article at: <https://dx.doi.org/10.21037/tp-22-381>

Introduction

Juvenile myelomonocytic leukemia (JMML) is a unique myelodysplastic/myeloproliferative neoplasm caused by the excessive proliferation of monocytes and granulocytes in infancy/early childhood (1). Its clinical manifestations include hepatosplenomegaly, lymphadenopathy, skin rash, leukocytosis, monocytosis, thrombocytopenia, anemia, and respiratory failure. With a global annual incidence of 1.2/1,000,000, JMML accounts for 2–3% of all hematological malignancies. The median age of JMML patients at the time of diagnosis is 2 years, and the male-to-female ratio is 2–3 to 1 (2). Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only cure for JMML. However, the low 5-year overall survival rate of 50–60% and the high post-HSCT recurrence rate remain major challenges for allo-HSCT (3). Recurrence is still the main reason for treatment failure in JMML patients.

Approximately 90% of JMML patients harbor germline or somatic mutations in Protein Tyrosine Phosphatase Non-Receptor Type 11 (*PTPN11*), NRAS Proto-Oncogene, GTPase (*NRAS*), KRAS Proto-Oncogene, GTPase (*KRAS*), Cbl Proto-Oncogene (*CBL*), or Neurofibromin 1 (*NF1*) (4). The mutation of these genes can activate the RAS signaling pathway (5). Epigenetics is the study of heritable alterations in gene expression that are not due to changes in the deoxyribonucleic acid (DNA) sequence. Epigenetic modifications alter DNA accessibility and/or the chromatin structure by which the expression levels of certain genes are regulated (6). DNA methylation (DNAm) involves the addition of a methyl group at position C5 in the DNA cytosine ring catalyzed by DNA methyltransferase enzymes (7). As an epigenetic mechanism involving the transfer of a methyl group onto the C5 position of the cytosine to form 5-methylcytosine-, the DNAm patterns observed in cancer genomes can be classified as either gene promoter hypomethylated and hypermethylated. CpG islands (CGIs) located in promoter regions in normal human tissues are in a hypomethylated state. However, the promoter hypermethylation of tumor suppressor genes can silence those genes and cause cancer (8). Thus, DNAm is an important aspect to consider when studying human diseases. Whole-genome bisulfite sequencing (WGBS) can detect the precise boundaries between methylated and unmethylated regions at single-base resolution and is considered the gold-standard method for DNAm analysis (9).

A study showed that some genes are hypermethylated or have superhigh methylation in JMML patients. This study

also reported 4 hypermethylated genes (i.e., *BMP4*, *CALCA*, *CDKN2B*, and *RARB*) (10). Previous studies have shown an association between activation of the DNA methylation machinery and specific JMML mutational profiles (11). Moreover, numerous studies have suggested that aberrant DNAm is linked to poor outcomes in JMML (10,12,13). However, clinical outcomes were significantly improved by treatment with the DNA-hypomethylating agent azacitidine prior to HSCT in patients with JMML (14). Thus, DNA hypermethylation is a novel independent prognostic factor for the poor prognosis of JMML (15). Identifying promising key genes associated with the progression and prognosis of JMML could lead to a marked improvement in the long-term survival of patients. Previous research has mainly focused on quantitative measurements of DNAm in large cohorts using the Infinium Human Methylation 450 Bead Chip (Illumina), quantitative high-resolution mass spectrometry (Sequenom MassARRAY), or bisulfite conversion and pyrosequencing techniques (13,16). To the best of the authors' knowledge, the relationship between gene methylation and the carcinogenesis of JMML has not been reported. Monozygotic (MZ) twins essentially share identical genomes and early-childhood family environments. An MZ twin study is thus an ideal approach for examining the effects of epigenetic modifications on various diseases. In this study, we conducted the WGBS of twins, a JMML patient and his healthy brother, and data mined from a Gene Expression Omnibus (GEO) data set to explore the causative genes and their potential effects on JMML. We present the following article in accordance with the MDAR reporting checklist (available at <https://tp.amegroups.com/article/view/10.21037/tp-22-381/rc>).

Methods

General information about the patient

The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by the Medical Ethics Committees of Nanfang Hospital, Southern Medical University (No. NFEC-2020-203). Before participating in this study, the patient's parents provided written informed consent. The patient was a 6-year-old boy diagnosed with JMML. On first admission, his white blood cell count was $42.79 \times 10^9/L$, his monocyte count was $13.48 \times 10^9/L$, his platelet count was $21 \times 10^9/L$, and his hemoglobin was 21 g/dL. The examination showed that the bone marrow of the patient contained 8% naive

granulocytes and 7% promyelocytes. The cytogenetic analysis showed a normal karyotype (46, XY), while targeted next-generation sequencing revealed an NF1 (S1399fs/R1748X) mutation. A physical examination showed splenomegaly, with a mean spleen size of 7 cm under the costal margin, and hepatomegaly, with a mean liver size of 2 cm under the costal margin. The patient appeared pale and had many café-au-lait spots on his lower limbs and trunk. His older brother was in good health.

Sample preparation

Bone marrow samples of the patient and peripheral blood samples of his older sibling and a healthy donor were collected. Total DNA from the above-mentioned samples was extracted using DNA extraction kits (TIANGEN, Beijing, China) following the manufacturer's protocol.

WGBS

Isolated genomic DNA was sheared into fragments of 100–300 bp in length. The 3' and 5' overhangs were repaired to create blunt ends, and a single "A" was added to the 3' end of the blunt fragment. Methylated adapters were ligated to the A-tailed fragment and bisulfite modified using a ZYMO EZ DNA Methylation-Gold Kit. A final polymerase chain reaction (PCR) amplification step was then performed for library qualification. Only the qualified library with the targeted size range was sent for sequencing.

Genome-wide methylation analysis and gene set enrichment analysis

Global DNAm profiles in all 3 samples were examined. The data were then analyzed by a pairwise comparison to identify the key genes. DNA methylation in eukaryotes occurs on cytosine bases in the context of CG, CHG, and CHH (H = A, C, or T). First, the CG, CHG, and CHH methylation in each sample were analyzed separately to compare the DNAm features. Next, the average DNAm levels of 7 different transcription elements in the genome, including the upstream region, first exon, first intron, internal exon, internal intron, last exon, and downstream region, were analyzed. Next, the differentially methylated regions (DMRs) among the samples were analyzed and compared. We performed a Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis and a Gene Ontology (GO) enrichment analysis of the DMR-

related genes to explore the role of epigenetic variations in pathways and biological processes and identified the overlapping differential signaling pathways. Network an enrichment analysis of the overlapping genes was performed using Cytoscape and Search Tool for the Retrieval of Interacting Genes/Proteins (STRING), which are gene/protein interaction databases, to identify the hub genes.

Real-time qPCR

The total ribonucleic acid (RNA) was extracted using TRIzol reagent (Invitrogen) from bone marrow blood samples from 3 JMML patients and peripheral blood samples from 3 healthy donors, and complementary DNA (cDNA) was reverse transcribed using a cDNA synthesis kit (Yeasen, Shanghai, China). The quantitative gene expression analysis was performed in an ABI7500 Real-Time PCR System (Applied Biosystems, California, USA) with a quantitative PCR (qPCR) SYBR Green Master Mix Kit (Yeasen, Shanghai, China). β -actin was used as the housekeeping gene, and the $2^{-\Delta\Delta C_t}$ method was used to quantify the relative expression levels of the genes of interest. The primers used to amplify cystic fibrosis transmembrane conductance regulator (*CFTR*) and β -actin are listed in Table S1.

Data mining and survival analysis

A data mining platform was used to query the expression level data for the hub genes identified in the healthy controls and the JMML patient samples in the GEO database, and differences between the means were compared by using a 2-tailed Student's *t*-test. For the survival analysis, the samples were divided into 2 groups according to the median expression levels of the hub genes, and the overall survival rates of the 2 groups were compared. A result was deemed to be statistically significant if the P value was <0.05.

Results

The analysis showed that the CHG and CHH methylation levels in the 3 children were similar. However, the distribution of cytosine methylation (mC) and CG methylation (mCG) in the JMML patients differed significantly between the healthy sibling and the healthy control (see Figure 1). We also analyzed the average DNAm levels of different transcription elements in the genomes of the 3 subjects and found no significant differences (see Figure 2).




Figure 1 Schematic representations of the cytosine methylation levels in each subject, as determined by WGBS. The x-axis shows the methylation level. (A) Cytosine methylation levels in the healthy control. (B) Cytosine methylation levels in the healthy control MZ twin. (C) Cytosine methylation levels in the patient. WGBS, whole-genome bisulfite sequencing; MZ, monozygotic; C, cytosine; G, guanine; CHG, where H is non-G nucleotides.

A KEGG pathway enrichment analysis and GO functional annotation analysis were performed on the DMR-associated genes in the 3 subjects. The DMR-related genes in the subjects had high consistency in functional clustering ($P > 0.05$; see *Figure 3*). Interestingly, we found no significant differences between the healthy controls and the patient in the genes, but the results of KEGG pathway enrichment analysis showed significant differences in multiple signaling pathways in the promoter region ($P < 0.01$; see *Figure 4* and <https://cdn.amegroups.cn/static/public/tp-22-381-1.xlsx>, <https://cdn.amegroups.cn/static/public/tp-22-381-2.xlsx>). As the Venn diagram analysis shows, 57 pathways, including the RAS signaling pathway and the pathways associated with cancer, were significantly enriched and overlapped in the 3 subjects (see *Figure 5* and <https://cdn.amegroups.cn/static/public/tp-22-381-3.xlsx>).

We performed a gene set enrichment analysis followed by network visualization of the gene data in the 57 overlapping pathways using the Cytoscape and STRING databases. The nodes represent the indicated genes, and the colored nodes

represent the genes enriched in certain signaling pathways. The gene set enrichment analysis revealed that the node in red (i.e., CFTR) was the hub gene (see *Figure 6*).

qPCR was used for validation

The relative expression levels of the target genes were verified in the 3 selected JMML patients and 3 healthy children's bone marrow or peripheral blood. The leukemia group showed slightly higher expression levels of CFTR; however, the difference was not statistically significant ($P = 0.22$; see *Figure 7*).

Data mining and statistical analysis

Publicly available data from the GEO database (<https://www.ncbi.nlm.nih.gov/gds/>) were mined. We removed batch effects between the 2 cohorts using the ComBat function in the sva package (17). The mean values between the patients and controls were compared using 2-tailed *t*-tests. As the




Figure 2 Methylation trends in gene regions. (A) Methylation trends in the healthy control. (B) Methylation trends in the healthy control MZ twin. (C) Methylation trends in the patient. MZ, monozygotic; C, cytosine; G, guanine; CHG, where H is non-G nucleotides.

box plot shows (see *Figure 8A*), the *CFTR* expression levels did not differ significantly between the JMML patients and healthy donors (GEO: GSE71935–JMML =38, normal =9; GEO: GSE71449–JMML =44, normal =7; $P=0.81$). However, according to the median gene expression levels in the microarray analysis, we divided patients into low- and high-expression subgroups. The Kaplan-Meier curve for the 82 well-defined JMML patients enrolled in the database revealed that higher *CFTR* expression was linked to lower survival probability ($P=0.019$; see *Figure 8B*). A comparison of the different prognosis subgroups of the JMML patients with the healthy controls showed that the expression of *CFTR* was significantly elevated in the poor prognosis group ($P=0.0049$; see *Figure 8C*). Conversely, patients with a lower expression level of *CFTR* may had a relatively better prognosis ($P=0.00097$; see *Figure 8D*).

Discussion

JMML is a clonal myeloproliferative/myelodysplastic neoplasia. Approximately 35% of JMML patients who

receive HSCT relapse within 5 years, indicating the strong need for a better understanding of the molecular mechanisms of JMML (3). Our study identified the important role of DNAm in the development and progression of JMML. A total of 57 overlapping signaling pathways, including RAS, were identified as target pathways that were involved in the pathogenesis of JMML. Some studies have described candidate genes that are transcriptionally regulated by methylation in JMML (10,12); however, this study is the first to show that *CFTR* gene methylation is significantly correlated with JMML. A total of 5 signaling pathways (i.e., the Cyclic Adenosine monophosphate (cAMP) signaling, AMP-activated protein kinase (AMPK) signaling, bile secretion, gastric acid secretion, and pancreatic secretion pathways) were identified in this study (see <https://cdn.amegroups.com/static/public/tp-22-381-4.xlsx>). Due to the limited sample size, no significant difference between the JMML patients and healthy children was found in relation to the expression of *CFTR*. However, a survival analysis of a larger cohort indicated that patients with high expression levels of *CFTR*




Figure 3 GO enrichment analysis of DMR-associated genes. (A,B) Expression of DMR-related genes and promoters between the twins. (C,D) Expression of DMR-related genes and promoters between the JMML patient and the healthy controls. GO, Gene Ontology; DMR, differentially methylated regions; JMML, juvenile myelomonocytic leukemia.

may exhibit a poorer prognosis than patients with low expression levels of *CFTR*.

CFTR, which is critical for carcinogenesis, was identified as one of the hub genes (18). *CFTR* is a glycoprotein with 1480 amino acids that belongs to the family of Adenosine triphosphate binding cassette (ABC) transporters (15). ABC transporters are frequently overexpressed in metastatic cancers, contributing to chemoresistance (19). Additionally, *CFTR* is a cAMP-regulated chloride channel that contains 2 nucleotide-binding domains (NBDs) (i.e., NBD1, and NBD2), and a cytosolic region called the R domain in addition to 12 transmembrane helices (15). A function of *CFTR* is to transport Cl⁻ and HCO₃⁻, and it also

regulates other ion channels (Na⁺, K⁺, Ca₂₊, and other Cl⁻ channels) (20-22). Additionally, *CFTR* also has roles in osmoregulation, membrane potential maintenance, lipid homeostasis, cell polarity, the metabolism of glucose and other substrates, oxidative stress, inflammation, mucus production, microbiome alterations, pH regulation, cell motility, autophagy, mitochondrial dysfunction, apoptosis, cell polarity, cell-cell contact, stem cell function, and cellular immune responses (23-33). Some studies have shown multiple associations between *CFTR* and cancer; however, its expression levels vary between different types of tumors. DNAm is the major epigenetic approach for gene regulation, and the destruction of DNAm is related to




Figure 4 Bubble diagram of KEGG enrichment analysis results. (A,B) Pathway enrichment analysis of DMR-associated genes and relevant promoters between the twins. (C,D) Pathway enrichment analysis of DMR-associated genes and relevant promoters between the JMML patient and the healthy controls. KEGG, Kyoto Encyclopedia of Genes and Genomes; DMR, differentially methylated regions; JMML, juvenile myelomonocytic leukemia.

a variety of diseases (34). The downregulation of the *CFTR* gene by promoter methylation has been demonstrated in various cancer types, including lung cancer (35), liver cancer (36), and head and neck cancer (37). However, *CFTR* is overexpressed in other cancers, such as ovarian cancer (38). This discrepancy indicates that the *CFTR* gene may act as both a proto-oncogene and an anti-oncogene.

The dual role of *CFTR* may be linked to its complex gene expression pattern, and the interaction of its promoter with intronic enhancers may coordinate gene transcription (39,40). In addition to being expressed

in actively proliferating epithelial cells, *CFTR* is also widely expressed in immune cells of the blood system and exerts biological functions, and its anion transport and regulation characteristics are the same as those of epithelial cells (41,42). The epigenetic regulation of *CFTR* has been discovered in other solid tumors, but very few studies of hematologic malignancies have been reported. Indeed, until 2017, only 1 study had shown that *CFTR* acts as an oncogene in Ph+ acute lymphoblastic leukemia (Ph+ALL) (43), and the expression level of the *CFTR* in Ph+ALL patients was found to be higher than that




Figure 5 Venn diagram showing the overlap among the 3 subjects. (A) Pathway enrichment analysis of the differentially expressed genes between the twins (light color). (B) Pathway enrichment analysis of the differentially expressed genes between JMML patients and healthy controls. Pathway enrichment analysis of the overlapping differentially expressed genes. JMML, juvenile myelomonocytic leukemia.

of healthy controls in another study (44). However, the relationship between *CFTR* and the development of JMML remains unclear.

In this study, consistent with similar results for other solid tumors, we found that the promoter of *CFTR* was hypermethylated in JMML patients. The *CFTR* promoter is a “housekeeping” type promoter rich in CpG. In addition to promoter methylation, hypoxia-responsive elements, intronic enhancers, and insulator elements that functionally interact with promoters in a cell-type-specific manner can also partially control the spatial regulation of CpG *CFTR* expression (45). Generally, DNA promoter methylation and gene expression are negatively correlated, but the high expression levels of some genes can be maintained even when their promoter regions are methylated (46). Further, promoter methylation status has been shown to be correlated with prognosis; for example, the hypermethylation of *CFTR* was found to be associated with an unfavorable survival rate in patients with prostate cancer (47).

Based on the role of *CFTR* in other tumors and the results of our methylation analysis, it is reasonable to assume that *CFTR* is an important JMML-associated gene. Thus, we downloaded microarray data sets and clinical follow-up data from the GEO database. The Kaplan-Meier curves revealed that high *CFTR* expression was associated with inferior prognosis in JMML, suggesting that *CFTR* and JMML may have a close relationship. However, this possibility requires further exploration.

Autophagy has emerged as an effective escape mechanism for promoting tolerance to chemotherapeutic drugs, ultimately leading to poor clinical outcomes (48). The constitutive activation of the RAS signaling pathway, the main pathogenic mechanism of JMML, is closely related to autophagy. Inhibition of KRAS→RAF→MEK→ERK signaling triggers autophagy, protecting cancer cells from the cytotoxic effects of RAS signaling pathway inhibition (49). However, high expression of *CFTR* may lead to autophagy and resistance to chemotherapeutic drugs in cancer cells (50). In terms of treatment efficiency, there is currently no type of chemotherapy that can lead to long-term remission in JMML patients.

Studies have shown that *CFTR* expression is also upregulated in ovarian cancer (37). The Ras-MAPK/Erk-ETS1/*CFTR*1 axis was found to be upregulated in ovarian cancer cell lines. This upregulation may increase the proliferation and invasion and reduce the drug absorption and apoptosis of tumor cells, ultimately resulting in chemotherapeutic resistance (51). *ETS1*, a main downstream effector in the Ras/ERK signaling pathway, is generally considered a transcriptional activator and is commonly hyperactivated in cancer. More specifically, the Ras-MAPK signaling pathway can be activated by *ETS1* via a dual functional role (52). Increased *ETS1* expression in ovarian cancer was found to be associated with a poor prognosis (53), and *ETS1* can regulate the expression of *CFTR* by binding to its promoter regions (50). These findings suggest that *CFTR* is associated with the ETS1 and Ras signaling pathways. Additionally, the overexpression of *CFTR* in serous ovarian cancer can activate the c-Src signaling pathways (54), which cooperate with the RAS signaling pathway to promote tumorigenesis (55). Despite this evidence, more studies need to be conducted to demonstrate the direct relationship between the overexpression of *CFTR* and the activation of the RAS/ERK signaling pathway.

Conversely, the high expression of *CFTR* is positively correlated with nuclear factor kappa beta (NF-κB) activation (56). Activated NF-κB binds to the src homology 2 (SH2) domain-containing tyrosine phosphatase-2 (SHP2) promoter, leading to increased SHP2 expression, which enhances the activation of the RAS/RAF/MEK/ERK pathway (57). The constitutive activation of the RAS pathway is the main pathogenic mechanism of JMML (4,5). Conversely, microRNA -150-5p, a small non-coding RNA, was discovered to play roles in both cancer and autoimmune disease (58,59). *CFTR*-mediated




Figure 6 Network visualization based on pathway enrichment analysis with Cytoscape and STRING. STRING, Search Tool for the Retrieval of Interacting Genes/Proteins.

HCO₃⁻ influx can activate soluble adenylate cyclase (sAC), which in turn activates protein kinase A (PKA)-dependent NF-κB signaling (60). Activated NF-κB1 interacts with miR-150-5p, which negatively regulates the miR-150-5p expression level (61). The downregulation of miR-150-5p leads to the phosphorylation of *STAT5b* and activates *KRAS*, *NRAS*, *NF1*, and *PTPN11* in JMML (62). This observation suggests that microRNAs might function as

intermediate links between *CFTR* and JMML pathogenesis/disease progression. Thus, we speculate that *CFTR* and the pathogenesis of JMML may be closely connected via RAS pathway regulation. Further investigations urgently need to be conducted to identify the mechanisms underlying this relationship. Subsequent research work will focus on genome-wide methylation analysis in expanded samples of JMML patients, and functional verification at the cellular level.




Figure 7 Validation of RNA-seq data by RT-qPCR. Relative expression level of CFTR determined by RT-qPCR. HC, healthy control; JMML, juvenile myelomonocytic leukemia; CFTR, cystic fibrosis transmembrane conductance regulator; RT-qPCR, real-time quantitative polymerase chain reaction; ns, no significance.

This was a preliminary laboratory study; thus, further investigation of *CFTR* function both *in vivo* and *in vitro* are required, and more investigations are needed to identify the mechanisms of *CFTR* in JMML development and progression. In future clinical research, to evaluate the relationship between *CFTR* promoter methylation and the clinical prognosis of JMML, we will increase the number of cases to dynamically monitor any changes in *CFTR* promoter methylation in JMML patients during treatment. Due to restrictions related to our sample size, our research lacked genome-wide methylation data and the corresponding gene expression profiling data from a large sample. In the next study, the sample size needs to be increased to elucidate this mechanism through a more thorough experimental analysis.

In conclusion, this study was the first to show that the promoter of *CFTR* is hypermethylated in JMML. This was a preliminary laboratory study but combined with the clinical data demonstrated in the study, we are of the view




Figure 8 Prognostic value of CFTR for long-term survival in patients with JMML. (A) Differential expression of CFTR between normal (n=16) and JMML (n=82) samples. (B) Kaplan-Meier analysis of overall survival in JMML patients. (C,D) Differential expression of CFTR between the normal (n=16) and the high (n=35) and low (n=47) expression subgroups of samples. **, P<0.01. ***, P<0.001. JMML, juvenile myelomonocytic leukemia; CFTR, cystic fibrosis transmembrane conductance regulator. ns, no significance.

that *CFTR* could be a promising diagnostic, therapeutic, and prognostic biomarker for JMML. However, further investigations of *CFTR* function both *in vivo* and *in vitro* are required, and more investigations are needed to reveal the role of the *CFTR* gene in JMML development and progression. In future clinical research, to deepen the knowledge of the relationship between *CFTR* promoter methylation and the clinical prognosis of JMML, the authors will increase the sample size to dynamically monitor the changes in *CFTR* promoter methylation in JMML patients during treatment. Genome-wide methylation data of more cases will also be taken into consideration to elucidate the matter.

Acknowledgments

We would like to thank the subjects and their parents for participating in this study.

Funding: This study was supported by the Clinical Research Program of Nanfang Hospital, Southern Medical University (No. 2018CR042), the Clinical Research Startup Program of Southern Medical University by High-Level University Construction Funding of Guangdong Provincial Department of Education (No. LC2016ZD017), and the Science and Technology Planning Project of Guangdong Province of China (No. 2016A020215102, to XW).

Footnote

Reporting Checklist: The authors have completed the MDAR reporting checklist. Available at <https://tp.amegroups.com/article/view/10.21037/tp-22-381/rc>

Data Sharing Statement: Available at <https://tp.amegroups.com/article/view/10.21037/tp-22-381/dss>

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at <https://tp.amegroups.com/article/view/10.21037/tp-22-381/coif>). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by the Medical Ethics Committees of Nanfang Hospital, Southern Medical

University (No. NFEC-2020-203). Before participating in this study, the patient's parents provided written informed consent.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. Hasle H, Kerndrup G, Jacobsen BB. Childhood myelodysplastic syndrome in Denmark: incidence and predisposing conditions. *Leukemia* 1995;9:1569-72.
2. Loh ML. Childhood myelodysplastic syndrome: focus on the approach to diagnosis and treatment of juvenile myelomonocytic leukemia. *Hematology Am Soc Hematol Educ Program* 2010;2010:357-62.
3. Locatelli F, Nöllke P, Zecca M, et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. *Blood* 2005;105:410-9.
4. Gupta AK, Meena JP, Chopra A, et al. Juvenile myelomonocytic leukemia-A comprehensive review and recent advances in management. *Am J Blood Res* 2021;11:1-21.
5. Gazin C, Wajapeyee N, Gobeil S, et al. An elaborate pathway required for Ras-mediated epigenetic silencing. *Nature* 2007;449:1073-7.
6. Handy DE, Castro R, Loscalzo J. Epigenetic modifications: basic mechanisms and role in cardiovascular disease. *Circulation* 2011;123:2145-56.
7. Allis CD. *Epigenetics*. New York, NY: CSHL Press, 2007.
8. Weaver IC, Cervoni N, Champagne FA, et al. Epigenetic programming by maternal behavior. *Nat Neurosci* 2004;7:847-54.
9. Cokus SJ, Feng S, Zhang X, et al. Shotgun bisulphite sequencing of the Arabidopsis genome reveals DNA methylation patterning. *Nature* 2008;452:215-9.
10. Olk-Batz C, Poetsch AR, Nöllke P, et al. Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome. *Blood* 2011;117:4871-80.
11. Lipka D.B., Witte T., Toth R., et al. RAS-pathway

- mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia. *Nat. Commun.* 2017;8:2126.
12. Wilhelm T, Lipka DB, Witte T, et al. Epigenetic silencing of AKAP12 in juvenile myelomonocytic leukemia. *Epigenetics* 2016;11:110-9.
 13. Sakaguchi H, Muramatsu H, Okuno Y, et al. Aberrant DNA Methylation Is Associated with a Poor Outcome in Juvenile Myelomonocytic Leukemia. *PLoS One* 2015;10:e0145394.
 14. Locatelli F, Niemeyer CM. How I treat juvenile myelomonocytic leukemia. *Blood* 2015;125:1083-90.
 15. Schönung M., Meyer J., Nöllke P., et al. International consensus definition of DNA methylation subgroups in juvenile myelomonocytic leukemia. *Clin. Cancer Res.* 2021;27:158.
 16. Lipka DB, Witte T, Toth R, et al. RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia. *Nat Commun* 2017;8:2126.
 17. Leek JT, Johnson WE, Parker HS, et al. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. *Bioinformatics* 2012;28:882-3.
 18. Guo Y, Xing Y. Weighted gene co-expression network analysis of pneumocytes under exposure to a carcinogenic dose of chloroprene. *Life Sci* 2016;151:339-47.
 19. He J, Fortunati E, Liu DX, et al. Pleiotropic Roles of ABC Transporters in Breast Cancer. *Int J Mol Sci* 2021;22:3199.
 20. Anderson MP, Gregory RJ, Thompson S, et al. Demonstration that CFTR is a chloride channel by alteration of its anion selectivity. *Science* 1991;253:202-5.
 21. Quinton PM. The neglected ion: HCO₃⁻. *Nat Med* 2001;7:292-3.
 22. Anderson KJ, Cormier RT, Scott PM. Role of ion channels in gastrointestinal cancer. *World J Gastroenterol* 2019;25:5732-72.
 23. Prevarskaya N, Skryma R, Shuba Y. Ion Channels in Cancer: Are Cancer Hallmarks Oncochannelopathies? *Physiol Rev* 2018;98:559-621.
 24. Lastraioli E, Iorio J, Arcangeli A. Ion channel expression as promising cancer biomarker. *Biochim Biophys Acta* 2015;1848:2685-702.
 25. Pankonien I, Quaresma MC, Rodrigues CS, et al. CFTR, Cell Junctions and the Cytoskeleton. *Int J Mol Sci* 2022;23:2688.
 26. Keown K, Brown R, Doherty DF, et al. Airway Inflammation and Host Responses in the Era of CFTR Modulators. *Int J Mol Sci* 2020;21:6379.
 27. Vernocchi P, Del Chierico F, Russo A, et al. Gut microbiota signatures in cystic fibrosis: Loss of host CFTR function drives the microbiota enterophenotype. *PLoS One* 2018;13:e0208171.
 28. Kleme ML, Sané AT, Garofalo C, et al. Targeted CFTR gene disruption with zinc-finger nucleases in human intestinal epithelial cells induces oxidative stress and inflammation. *Int J Biochem Cell Biol* 2016;74:84-94.
 29. Kleme ML, Sané A, Garofalo C, et al. CFTR Deletion Confers Mitochondrial Dysfunction and Disrupts Lipid Homeostasis in Intestinal Epithelial Cells. *Nutrients* 2018;10:836.
 30. Xia X, Wang J, Liu Y, et al. Lower Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Promotes the Proliferation and Migration of Endometrial Carcinoma. *Med Sci Monit* 2017;23:966-74.
 31. Liou TG. The Clinical Biology of Cystic Fibrosis Transmembrane Regulator Protein: Its Role and Function in Extrapulmonary Disease. *Chest* 2019;155:605-16.
 32. Vilella VR, Venerando A, Cozza G, et al. A pathogenic role for cystic fibrosis transmembrane conductance regulator in celiac disease. *EMBO J* 2019;38:e100101.
 33. Gelfond D, Heltshe S, Ma C, et al. Impact of CFTR Modulation on Intestinal pH, Motility, and Clinical Outcomes in Patients With Cystic Fibrosis and the G551D Mutation. *Clin Transl Gastroenterol* 2017;8:e81.
 34. Egger G, Liang G, Aparicio A, et al. Epigenetics in human disease and prospects for epigenetic therapy. *Nature* 2004;429:457-63.
 35. Tian F, Zhao J, Fan X, et al. Weighted gene co-expression network analysis in identification of metastasis-related genes of lung squamous cell carcinoma based on the Cancer Genome Atlas database. *J Thorac Dis* 2017;9:42-53.
 36. Moribe T, Iizuka N, Miura T, et al. Methylation of multiple genes as molecular markers for diagnosis of a small, well-differentiated hepatocellular carcinoma. *Int J Cancer* 2009;125:388-97.
 37. Shin Y, Kim M, Won J, et al. Epigenetic Modification of CFTR in Head and Neck Cancer. *J Clin Med* 2020;9:734.
 38. Zhu LC, Hu ZH, Liu JJ, et al. Whole Genome Expression Profiling Analysis of Metastasis and Drug-resistance-related Genes in Epithelial Ovarian Cancer Cells. *Zhongguo Yi Xue Ke Xue Yuan Xue Bao* 2015;37:662-73.
 39. Ott CJ, Suszko M, Blackledge NP, et al. A complex intronic enhancer regulates expression of the CFTR gene by direct interaction with the promoter. *J Cell Mol Med* 2009;13:680-92.
 40. Lewandowska MA, Costa FF, Bischof JM, et al. Multiple

- mechanisms influence regulation of the cystic fibrosis transmembrane conductance regulator gene promoter. *Am J Respir Cell Mol Biol* 2010;43:334-41.
41. Yoshimura K, Nakamura H, Trapnell BC, et al. Expression of the cystic fibrosis transmembrane conductance regulator gene in cells of non-epithelial origin. *Nucleic Acids Res* 1991;19:5417-23.
 42. Sun H, Wang Y, Zhang J, et al. CFTR mutation enhances Dishevelled degradation and results in impairment of Wnt-dependent hematopoiesis. *Cell Death Dis* 2018;9:275.
 43. Neviani P, Santhanam R, Trotta R, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. *Cancer Cell* 2005;8:355-68.
 44. Yang X, Yan T, Gong Y, et al. High CFTR expression in Philadelphia chromosome-positive acute leukemia protects and maintains continuous activation of BCR-ABL and related signaling pathways in combination with PP2A. *Oncotarget* 2017;8:24437-48.
 45. Gillen AE, Harris A. Transcriptional regulation of CFTR gene expression. *Front Biosci (Elite Ed)*. 2012;4:587-92.
 46. Guillaumet-Adkins A, Richter J, Odero MD, et al. Hypermethylation of the alternative AWT1 promoter in hematological malignancies is a highly specific marker for acute myeloid leukemias despite high expression levels. *J Hematol Oncol* 2014;7:4.
 47. Ashour N, Angulo JC, Andrés G, et al. A DNA hypermethylation profile reveals new potential biomarkers for prostate cancer diagnosis and prognosis. *Prostate* 2014;74:1171-82.
 48. Levy JMM, Towers CG, Thorburn A. Targeting autophagy in cancer. *Nat Rev Cancer* 2017;17:528-42.
 49. Kinsey CG, Camolotto SA, Boespflug AM, et al. Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers. *Nat Med* 2019;25:620-7.
 50. Zhu Q, Li H, Liu Y, et al. Knockdown of CFTR enhances sensitivity of prostate cancer cells to cisplatin via inhibition of autophagy. *Neoplasia* 2017;64:709-17.
 51. Rodriguez-Aguayo C, Bayraktar E, Ivan C, et al. PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis. *EBioMedicine* 2019;40:290-304.
 52. Plotnik JP, Budka JA, Ferris MW, et al. ETS1 is a genome-wide effector of RAS/ERK signaling in epithelial cells. *Nucleic Acids Res* 2014;42:11928-40.
 53. Prasad P, Roy SS. Glutamine regulates ovarian cancer cell migration and invasion through ETS1. *Heliyon* 2021;7:e07064.
 54. Xu J, Lin L, Yong M, et al. Adenovirus-mediated overexpression of cystic fibrosis transmembrane conductance regulator enhances invasiveness and motility of serous ovarian cancer cells. *Mol Med Rep* 2016;13:265-72.
 55. Shields DJ, Murphy EA, Desgrosellier JS, et al. Oncogenic Ras/Src cooperativity in pancreatic neoplasia. *Oncogene* 2011;30:2123-34.
 56. Wu Z, Peng X, Li J, et al. Constitutive activation of nuclear factor κB contributes to cystic fibrosis transmembrane conductance regulator expression and promotes human cervical cancer progression and poor prognosis. *Int J Gynecol Cancer* 2013;23:906-15.
 57. Nichols RJ, Haderk F, Stahlhut C, et al. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers. *Nat Cell Biol* 2018;20:1064-73.
 58. Chang WA, Tsai MJ, Hung JY, et al. miR-150-5p-Containing Extracellular Vesicles Are a New Immunoregulator That Favor the Progression of Lung Cancer in Hypoxic Microenvironments by Altering the Phenotype of NK Cells. *Cancers (Basel)* 2021;13:6252.
 59. Ying W, Tseng A, Chang RC, et al. miR-150 regulates obesity-associated insulin resistance by controlling B cell functions. *Sci Rep* 2016;6:20176.
 60. Lu YC, Chen H, Fok KL, et al. CFTR mediates bicarbonate-dependent activation of miR-125b in preimplantation embryo development. *Cell Res* 2012;22:1453-66.
 61. Ma Y, Liu Y, Hou H, et al. MiR-150 predicts survival in patients with sepsis and inhibits LPS-induced inflammatory factors and apoptosis by targeting NF-κB1 in human umbilical vein endothelial cells. *Biochem Biophys Res Commun* 2018;500:828-37.
 62. Leoncini PP, Bertaina A, Papaioannou D, et al. MicroRNA fingerprints in juvenile myelomonocytic leukemia (JMML) identified miR-150-5p as a tumor suppressor and potential target for treatment. *Oncotarget* 2016;7:55395-408.

Cite this article as: Yi TT, Yu JM, Liang YY, Wang SQ, Lin GC, Wu XD. Identification of cystic fibrosis transmembrane conductance regulator as a prognostic marker for juvenile myelomonocytic leukemia via the whole-genome bisulfite sequencing of monozygotic twins and data mining. *Transl Pediatr* 2022;11(9):1521-1533. doi: 10.21037/tp-22-381